Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for the Treatment of Scabies

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for the Treatment of Scabies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spinosad (Primary) ; Permethrin
  • Indications Scabies
  • Focus Registrational; Therapeutic Use
  • Sponsors ParaPRO

    • Most Recent Events

    • 12 Aug 2021 Pooled results (n=551) from 2 controlled clinical studies(NCT02485717 and NCT02485704) evaluating efficacy of spinosad 0.9% topical suspension in the eradication of scabies published in the Journal of the American Academy of Dermatology
    • 24 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2018 Planned primary completion date changed from 7 Sep 2018 to 19 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top